This study focuses on the prevention and management of cardiometabolic risk factors in healthy adults who are at risk of developing cardiovascular and metabolic diseases. Although participants are not diagnosed with clinical disease, the study aims to investigate the impact of Spirulina supplementation on early biomarkers associated with dyslipidemia, body fat accumulation, and renal function. These parameters are considered important indicators for the early prevention of non-communicable disea
Conditions
Interventions
Participants in the intervention group received Spirulina platensis powder supplement at a dose of 2 gram per day, administered orally in capsule form, for 12 consecutive weeks,Participants in the con
Intervention: Spirulina platensis powder supplement (2 gram/day),Control: Placebo capsule (maltodextrin)
Sponsors
The primary sponsor of this study is the University of Phayao, in collaboration with Thailand Science Park
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Thai males or females aged between 18 and 70 years 2. Body mass index (BMI) between 18.0 and 30.0 kilograms per square meter 3. Fasting triglyceride level greater than 90 mg per dL 4. Generally healthy as determined by medical history and screening examination 5. Willingness to maintain current lifestyle habits, including diet and physical activity, throughout the study 6. No plans to travel or relocate during the study period 7. Able to understand study procedures and comply with the study protocol
Exclusion criteria
Exclusion criteria: 1. History of chronic diseases such as cardiovascular disease, diabetes mellitus, chronic kidney disease, or liver disease 2. Currently taking lipid lowering medications, dietary supplements containing Spirulina, or any antioxidant products 3. Pregnant or breastfeeding women 4. History of allergy to algae, seaweed, or Spirulina products 5. Current smoker or alcohol consumption exceeding 7 drinks per week 6. Participation in another clinical trial within the past 3 months 7. Significant changes in diet or physical activity within the past 1 month 8. Any condition that, in the opinion of the investigator, would interfere with study participation or data interpretation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum total cholesterol Serum triglyceride Serum low-density lipoprotein cholesterol Serum high-density lipoprotein cholesterol Baseline and at week 12 after intervention Enzymatic colorimetric method using an automated clinical chemistry analyzer | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum creatinine Baseline and at week 12 after intervention Measured using enzymatic colorimetric method with an automated clinical chemistry analyzer | — |
Countries
Thailand
Contacts
Public ContactWittawas Sajjapong
University of Phayao, School of Medical Sciences, Division of Nutrition and Dietetics
Outcome results
None listed